Dianthus Corp - DNTH Aggregate Business Value
The price evolution of Dianthus Therapeutics (DNTH) reflects a current enterprise value of 3718.44. The business leverages its status as a leading biotech firm developing breakthrough therapies for severe immune failures. Currently, Dianthus Therapeutics (DNTH) is developing a pipeline of targeted inhibitors to combat neuromuscular pathologies, which are presently in the testing phase. The foundation for growth is rooted in a unique system of targeted complement inhibition for the treatment of autoimmune diseases.
Dianthus Therapeutics (DNTH) - metric breakdowns and financial figures
- share price and expert price forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Dianthus Therapeutics|DNTH - Long-Term Debt to Capital|Short-Term Debt to Capital dianthustx.com|DNTH - Company Debts|Debt to Net Assets Ratio Dianthus Therapeutics|DNTH - Company Long-Term Debt|Company Current Liabilities Dianthus Therapeutics|Quick Ratio dianthustx.com
- earnings and market ratios statistics:
Analysis of all company metrics:Dianthus Therapeutics Inc
An investor determines an asset's margin of safety by analyzing the total cost of acquisition. The development of unique long-acting antibodies for the therapy of autoimmune diseases creates high intrinsic value for Dianthus Therapeutics (DNTH). This enterprise value metric sums the company's market capitalization and liabilities while subtracting cash and cash equivalents. Such a methodology allows for an assessment of the actual scale of the business, excluding temporary liquid reserves. The asset is categorized as a high-risk biotechnological startup.
Competitors of Dianthus Therapeutics (DNTH)
ARGX: Business Value|BNTX: Real Price to Acquire Entire Company|Abivax Pharma - Aggregate Business Value|ADMA: Enterprise Value|protagonist-inc.com - Value Adjusted for Debt and Cash|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Pharvaris Corp (PHVS) - Total Company Value|Real Price to Acquire Entire Company AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Enterprise Value|Enterprise Value precigen.com|Real Price to Acquire Entire Company PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Value Adjusted for Debt and Cash|Enterprise Value UPB (Upstream Bio Corp)|Company Buyout Price Zenas Corp (ZBIO)|IMNM - Total Company Value|gossamerbio.com (GOSS) - Real Price to Acquire Entire Company|KalVista Pharmaceuticals, Inc. (KALV) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|Real Price to Acquire Entire Company PVLA|Enterprise Value Savara Pharma|Total Company Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Business Value|Enterprise Value ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Total Enterprise Value|RAPT Therapeutics - Enterprise Value|JBIO (Aerovate Therapeutics Inc) - Business Value|ACRS: Enterprise Value|KYTX - Company Buyout Price|TLSA (Tiziana Life Sciences Ltd) - Enterprise Value|Enterprise Value Cabaletta Bio Inc.|Total Company Value Ventyx Bio (VTYX)|Theratechnologies, Inc - Business Value|Avalo Therapeutics, Inc - Real Price to Acquire Entire Company|Aggregate Business Value ELDN (eledon.com)|Agenus Inc. - Enterprise Value|Value Adjusted for Debt and Cash CLYM (Climb Bio Inc.)|ZURA (Zura Bio) - Real Price to Acquire Entire Company|aTyr Pharmaceuticals (ATYR) - Enterprise Value|Total Company Value Adagene Inc|Ikena Oncology, Inc. (IMA) - Company Buyout Price|Real Price to Acquire Entire Company STTK (Shattuck Labs, Inc.)|EQ (equilliumbio.com) - Value Adjusted for Debt and Cash|Connect Biopharma Holdings Limited - Real Price to Acquire Entire Company|Aggregate Business Value IMUX (Immunic Therapeutics)|Atara Biotherapeutics Inc - Enterprise Value|Value Adjusted for Debt and Cash IFRX (InflaRx N.V.)|XFOR: Enterprise Value|Total Enterprise Value Adicet Bio, Inc. (ACET)|Total Company Value Celularity Inc|INMB: Value Adjusted for Debt and Cash|Enterprise Value BRNS|Enterprise Value kezarlifesciences.com (KZR)|Total Company Value SAB Biotherapeutics, Inc. SABS|AKTX (Akari Therapeutics PLC) - Full Business Value|Enlivex Therapeutics, Ltd. - Enterprise Value|Total Enterprise Value Q32 Bio Inc.|GOVX (GeoVax Labs, Inc.) - Real Price to Acquire Entire Company|edesabiotech.com (EDSA) - Enterprise Value|Real Price to Acquire Entire Company IBIO|CARM (Carisma Tx) - Aggregate Business Value|Enterprise Value XTLB|Company Buyout Price boltbio.com|Enterprise Value HCWB (HCW Biologics)|APVO - Real Price to Acquire Entire Company|AIM - Total Company Value|Company Buyout Price Aditxt ADTX|GRI: Enterprise Value|Business Value XRTX|Total Company Value Vyome Holdings Inc|Business Value REVB (revbiosciences.com)|Real Price to Acquire Entire Company INDP (Indaptus Therapeutics, Inc.)|Aggregate Business Value SCNI|Enterprise Value CALI (CalciMedica)|Value Adjusted for Debt and Cash AFMD|ALLK - Total Company Value|Full Business Value HOOK|IGMS: Enterprise Value|iTeos Therapeutics Inc - Value Adjusted for Debt and Cash|OCEA (Ocean Bio) - Enterprise Value|Enterprise Value TC BioPharm Ltd|Total Company Value Third Harmonic Bio (THRD)